Gingival metastasis of a mediastinal pulmonary sarcomatoid carcinoma: a case report

Qin, Zhonghua; Huang, Bin; Yu, Guiping; Zheng, Yu; Zhao, Ke

doi:10.1186/s13019-019-0991-y

Cited by 11 publications

(16 citation statements)

References 17 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our patient's CT findings also show simultaneous obstructive pneumonia and changes in the pleura and parenchyma secondary to the mass effect. As per Qin et al, PCS can occur with extensive tumor necrosis, and subpleural lesions have a tendency to invade the chest wall or pleura, explaining the chest wall nodule identified in our patient [11]. Intratumoral ossification is rare, but calcification is common if osteosarcoma or chondrosarcomatous component was part of the tumor.…”

Section: Discussionsupporting

confidence: 68%

Pulmonary Carcinosarcoma: A Rare Disease With Challenging Diagnosis and Treatment

Mekheal¹,

Kapoor²,

Roman³

et al. 2022

Cureus

View full text Add to dashboard Cite

Pulmonary carcinosarcoma (PCS) is a rare type of non-small cell cancer. Overall, middle-aged and older smokers are the most affected age and sex groups. The diagnosis of PCS is difficult due to the absence of characteristic imaging findings. Additionally, preoperative biopsies do not usually reflect the heterologous nature of this tumor. Given the rarity of such tumors and the challenging diagnosis, the prognostic factors have not been established, and the overall prognosis remains poor. The valid therapeutic options are still limited. Here, we report a rare case of metastatic PCS that was accidentally discovered by imaging and properly diagnosed after surgical resection. The clinicopathological features, diagnostic tools, genetic theories, prognosis, and therapeutic options of this rare cancer are also discussed.

show abstract

Section: Discussionsupporting

confidence: 68%

Pulmonary Carcinosarcoma: A Rare Disease With Challenging Diagnosis and Treatment

Mekheal¹,

Kapoor²,

Roman³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…34 Compared with females, carcinosarcomas are more common in males with a history of smoking. 33 , 42 From 1995 to 2011, only one review reported 42 cases of biphasic pulmonary blastoma (CBPC), showing that it is extremely rare among lung carcinomas. 43 …”

Section: Clinicopathological Characteristicsmentioning

confidence: 99%

“…Computed tomography (CT) diagnosis of PSC by Qin et al is summarized as follows: 33 (1) Peripheral tumors are more common than central ones, and lesions are always confined to the upper lobe. (2) Tumors are usually huge, with well-defined boundaries, and are round or quasi-circular.…”

Section: Imaging Characteristicsmentioning

confidence: 99%

Pulmonary sarcomatoid carcinoma: progress, treatment and expectations

Liu

et al. 2020

Ther Adv Med Oncol

View full text Add to dashboard Cite

Pulmonary sarcomatoid carcinoma (PSC) is a unique, highly invasive pulmonary malignancy with a poor prognosis, representing 0.1–0.4% of all malignant lung tumors. Because of its highly aggressive character and propensity for frequent metastasis, PSC shows low response rates to traditional treatments such as chemotherapy, radiotherapy, and neoadjuvant therapy. In recent years, considerable progress has been made in gene sequencing, targeted therapies, and immunotherapies. One of the most promising treatment approaches is the selection of mono-targeted or multi-targeted drugs according to tumor gene-mutation sites, such as epidermal growth factor receptor or vascular endothelial growth factor receptor 2 ( EGFR/VEGFR2), anaplastic lymphoma kinase ( ALK), and others. Another approach is the activation of therapeutic anti-tumor immunity via pathways including programmed cell-death protein-1/programmed cell-death ligand-1 ( PD-1/PD-L1), which has been used in individual cases. In this review, we will introduce the clinicopathologic features, molecular typing, and traditional treatments. We will also review the biological characteristics and the latest therapies for PSC. These novel therapies show promise in the management of PSC, and the outcomes of investigative trials will hopefully reveal a variety of treatment options for patients with PSC.

show abstract

“…CT images display that masses of peripheral PSCs are usually large, rounded, well-defined, often with necrotic areas, and with or without cavitation. Peripleural masses are usually subpleural and tend to invade the pleura or chest wall [ 6 ]. This 50-year-old patient was a man with a history of smoking, presenting a large subpleural tumor of 14 cm diameter in the right upper lobe, which was consistent with previous reports.…”

Section: Discussionmentioning

confidence: 99%

A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab

Sawatari

Izumi

Sone

et al. 2022

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

Pulmonary sarcomatoid carcinoma (PSC) is an extremely rare neoplasm with poor prognosis and no established treatment. A 50-year-old man presented with fever, was found to have a mass measuring 14 cm in the right upper lobe of the chest, along with right pleural effusion on computed tomography (CT). Positron emission tomography-CT revealed abnormal tracer uptake in the area corresponding to the mass in the upper lobe. Hence, convex-probe endobronchial ultrasound-guided transbronchial needle aspiration was performed. Histological examination revealed dense proliferation of spindle tumor cells and no programmed death-ligand 1 (PD-L1) expression. Thus, he was diagnosed with PSC (cT4N0M1a, clinical stage IVA), and four-agent combination chemotherapy with atezolizumab, carboplatin, paclitaxel, and bevacizumab was initiated. Marked shrinkage of the mass and symptomatic improvements were observed following the treatment initiation. Tumor shrinkage was further noted after shifting to maintenance therapy with atezolizumab and bevacizumab; the patient exhibited no symptom exacerbation 2 years later and continued the treatment. Our case showed that four-agent combination chemotherapy with atezolizumab, carboplatin, paclitaxel, and bevacizumab could be an effective treatment option for advanced PSC with or without PD-L1 expression.

show abstract

Gingival metastasis of a mediastinal pulmonary sarcomatoid carcinoma: a case report

Cited by 11 publications

References 17 publications

Pulmonary Carcinosarcoma: A Rare Disease With Challenging Diagnosis and Treatment

Pulmonary Carcinosarcoma: A Rare Disease With Challenging Diagnosis and Treatment

Pulmonary sarcomatoid carcinoma: progress, treatment and expectations

A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab

Contact Info

Product

Resources

About